-transparent.png){kind=logo}
Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. 2010
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
Gastroenterological Center, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan. akino@yokohama-cu.ac.jp
Hepatitis C virus (HCV) is the main causative agent of chronic liver disease, which may develop into liver cirrhosis and hepatocellular carcinoma. By using a recently developed reporter assay system in which genome-length HCV RNA replicates efficiently, we found that hydroxyurea (HU), a DNA synthesis inhibitor, inhibited HCV RNA replication. Moreover, we demonstrated that the anti-HCV activity of the combination of IFN-alpha and HU was higher than that of IFN-alpha alone. These results suggest that HU may be an effective anti-HCV reagent that can be used not only singly but also in combination with IFN-alpha to treat chronic hepatitis C.
Related Publications
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
May 2003,
The Journal of biological chemistry,
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
January 2013,
Current topics in microbiology and immunology,
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
November 1994,
Science (New York, N.Y.),
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
September 2004,
The Journal of organic chemistry,
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
May 2012,
Antiviral research,
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
June 2004,
Virus research,
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
May 2009,
Journal of medicinal chemistry,
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
June 2000,
Nephron,
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
May 2012,
The Journal of biological chemistry,
Akito Nozaki, and
Manabu Morimoto, and
Masaaki Kondo, and
Takashi Oshima, and
Kazushi Numata, and
Shin Fujisawa, and
Takeshi Kaneko, and
Eiji Miyajima, and
Satoshi Morita, and
Kyoko Mori, and
Masanori Ikeda, and
Nobuyuki Kato, and
Katsuaki Tanaka
January 2012,
PloS one,
